Related Experiment Videos
Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets
A C Tan1, J W Kruimel, T H Naber
1Department of Gastroenterology and Hepatology, University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. a.tan@hccnet.nl
Summary
Eosinophilic gastroenteritis, a rare condition, was treated successfully with oral budesonide tablets. This approach achieved long-term remission with minimal side effects, offering a novel therapeutic option.
Area of Science:
- Gastroenterology
- Immunology
Background:
- Eosinophilic gastroenteritis is a rare disorder characterized by eosinophilic infiltration of the gastrointestinal tract.
- Diagnosis often requires biopsy, and management can be challenging due to potential side effects of systemic corticosteroids.
Observation:
- A patient presented with upper abdominal pain, nausea, ascites, and peripheral eosinophilia.
- Initial treatment with prednisone yielded a partial response but required a minimum dose of 5 mg.
- Gastric involvement precluded the use of enteric-coated budesonide.
Findings:
- Oral budesonide tablets, originally intended for enema use, were administered to the patient.
- This treatment led to sustained remission for over two years.
- Budesonide provided a corticosteroid option with potentially fewer systemic side effects.
Implications:
- Oral budesonide tablets represent a viable therapeutic alternative for eosinophilic gastroenteritis, particularly with gastric involvement.
- This approach may offer a favorable safety profile compared to traditional systemic corticosteroids.
- Further research into budesonide's efficacy and safety in eosinophilic gastrointestinal diseases is warranted.